Literature DB >> 24678

Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea.

R J Chalmers, R H Johnson, H J Keogh, R N Nanda.   

Abstract

The growth hormone (hGH) and prolactin (hPRL) responses to oral bromocriptine were studied in two groups of patients with Huntington's chorea and in seven healthy control subjects. The patients included six patients who had previously been treated with phenothiazines and six patients who had not received phenothiazine treatment. All medication was stopped 72 hours before the investigation which involved taking blood samples for up to 210 minutes after taking bromocriptine (2.5 mg). Plasma samples were analysed for hGH and hPRL. There was no significant difference in basal hGH concentrations between the patients and control subjects. The hGH response to bromocriptine varied in the individual patients but the concentrations were significantly lower in the patients compared with the controls between 160 and 210 minutes. The basal concentrations of hPRL were also not different, apart from the findings of elevated hPRL concentrations in three patients previously treated with phenothiazines. The patients and control subjects showed a consistent fall in hPRL concentrations after taking bromocriptine. The lower peak hGH response to bromocriptine found in the patients suggests that there may be an alteration of dopaminergic neurones mediating hGH release.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24678      PMCID: PMC492981          DOI: 10.1136/jnnp.41.2.135

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  19 in total

1.  The acute effect of 2-bromo-a-ergocryptine (CB-154) on anterior pituitary hormones and free fatty acids in man.

Authors:  G Tolis; E J Pinter; H G Friesen
Journal:  Int J Clin Pharmacol Biopharm       Date:  1975-07

2.  Dopamine and basal ganglia diseases.

Authors:  A BARBEAU
Journal:  Arch Neurol       Date:  1961-01

3.  Homologous radioimmunoassay for human prolactin.

Authors:  A M Reuter; F Kennes; Y Gevaert; P Franchimont
Journal:  Int J Nucl Med Biol       Date:  1976-01

4.  Brain immunoreactive gonadotropin-releasing hormone in Huntington's chorea and in non-choreic subjects.

Authors:  E D Bird; S A Chiappa; G Fink
Journal:  Nature       Date:  1976-04-08       Impact factor: 49.962

5.  The effect of neuroleptics on serum prolactin in schizophrenic patients.

Authors:  H Y Meltzer; V S Fang
Journal:  Arch Gen Psychiatry       Date:  1976-03

6.  Huntington's disease: treatment with dipropylacetic acid and gamma-aminobutyric acid.

Authors:  I Shoulson; R Kartzinel; T N Chase
Journal:  Neurology       Date:  1976-01       Impact factor: 9.910

7.  Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.

Authors:  F Camanni; F Massara; L Belforte; G M Molinatti
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

8.  Plasma growth hormone concentrations in Huntington's chorea.

Authors:  O T Phillipson; E D Bird
Journal:  Clin Sci Mol Med       Date:  1976-06

9.  Bromocriptine in Huntington chorea.

Authors:  R Kartzinel; R D Hunt; D B Calne
Journal:  Arch Neurol       Date:  1976-07

10.  Altered growth hormone release in Huntington's chorea.

Authors:  H J Keogh; R H Johnson; R N Nanda; W R Sulaiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-03       Impact factor: 10.154

View more
  7 in total

Review 1.  Neuroendocrine markers of CNS drug effects.

Authors:  E C Johnstone; I N Ferrier
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

2.  Twenty-four hour plasma levels of growth hormone and prolactin in Huntington's disease.

Authors:  R Durso; C A Tamminga; S Ruggeri; A Denaro; S Kuo; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1983-12       Impact factor: 10.154

3.  Studies of hypothalamic function in Huntington's chorea.

Authors:  P J Lavin; I Bone; P Sheridan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-05       Impact factor: 10.154

Review 4.  The endocrine profile of bromocriptine: its application in endocrine diseases.

Authors:  I Lancranjan
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

5.  A 24-Hour Study of the Hypothalamo-Pituitary Axes in Huntington's Disease.

Authors:  Eirini Kalliolia; Edina Silajdžić; Rajasree Nambron; Seán J Costelloe; Nicholas G Martin; Nathan R Hill; Chris Frost; Hilary C Watt; Peter Hindmarsh; Maria Björkqvist; Thomas T Warner
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

6.  Neuroendocrine disturbances in Huntington's disease.

Authors:  Nadine Saleh; Stéphane Moutereau; Alexandra Durr; Pierre Krystkowiak; Jean-Philippe Azulay; Christine Tranchant; Emmanuel Broussolle; Françoise Morin; Anne-Catherine Bachoud-Lévi; Patrick Maison
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

Review 7.  A Critical Evaluation of Wet Biomarkers for Huntington's Disease: Current Status and Ways Forward.

Authors:  Edina Silajdžić; Maria Björkqvist
Journal:  J Huntingtons Dis       Date:  2018
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.